In a report released on February 20, Puneet Souda from Leerink Partners maintained a Buy rating on Guardant Health (GH – Research Report), with a price target of $65.00.
Puneet Souda has given his Buy rating due to a combination of factors that position Guardant Health favorably for growth. The company’s guidance for 2025 revenues exceeds expectations, with anticipated growth driven by the Shield CRC Screening program, which is well-supported by an expanding sales force. The guidance is considered conservative, leaving room for potential upward revisions, particularly as it does not include certain pricing benefits or contributions from international contracts.
Additionally, Guardant Health’s Shield product is gaining traction, achieving significant revenue and volume increases, with expectations for continued growth due to its advantage in the Medicare market. The absence of immediate competition and upcoming product launches, such as Shield v2 and multi-cancer data readouts, are seen as catalysts that could further enhance the company’s market position and stock value.
According to TipRanks, Souda is an analyst with an average return of -12.3% and a 30.44% success rate. Souda covers the Healthcare sector, focusing on stocks such as Natera, Hologic, and Illumina.
In another report released on February 21, Bernstein also maintained a Buy rating on the stock with a $60.00 price target.